Latest news
Stoke: 'Buy' Zorevunersen NDA SCN1A DS And STK-002 Advancement (NASDAQ:STOK) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 17:50:02 GMTStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates - BioSpaceBioSpace · Tue, 04 Aug 2026 02:30:55 GMTStoke Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Mon, 03 Aug 2026 22:03:51 GMTStoke Therapeutics reports Q2 2026 net loss $61.6M, $420M cash runway; Phase 3 zorevunersen enrollment complete - TradingViewTradingView · Mon, 03 Aug 2026 20:13:01 GMT